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Hypertension is a major modifiable risk factor, which sig-
nificantly and independently increases the risk of devel-
oping cardiovascular and renal complications [1].
Pharmacological treatment of hypertension aimed at
achieving the recommended therapeutic targets [i.e. blood
pressure (BP) levels below 140/90 mmHg] substantially
reduces the risk of complications in different clinical set-
tings [2]. Despite these benefits, worldwide rates of BP
control are still reported to be largely unsatisfactory, thus
contributing to a persistently high burden of hypertension-
related diseases [3, 4].
Over the last decades, several interventions have been
proposed at both national and local levels in order to
improve hypertension management and control, although
with various outcomes. Among these interventions, a larger
use of combination therapies, mostly in fixed formulations,
has been promoted by international guidelines in the recent
years. In fact, the use of combination therapies of different
drug classes, particularly when included in a single pill, has
demonstrated to improve patients’ adherence and compli-
ance to prescribed medications [5] and reduce incidence of
drug-related side effects in various clinical studies [6, 7]. In
addition, several randomized clinical trials have convinc-
ingly and independently demonstrated the clinical benefits
derived from such an approach in terms of reduced
incidence of major cardiovascular and renal complications,
beyond the BP lowering efficacy, with a good tolerability
profile [8–13]. Although there is currently only one ran-
domized clinical trial performed with a fixed dose combi-
nation therapy based on Angiotensin-Converting Enzyme
(ACE) inhibitor and either thiazide diuretic or calcium-
channel blocker in hypertensive patients with high car-
diovascular risk profile [14], it has been widely recognized
that antihypertensive strategies based on the use of these
drug classes can promote the achievement of better BP
control rates and reduce the hypertension-related burden of
cardiovascular diseases in several clinical settings.
On the basis of the currently available evidence, both
European [15] and Italian [16] guidelines promote the use
of combination therapies for the clinical management of
hypertension, suggesting the use of drugs inhibiting the
renin–angiotensin system (either ACE inhibitor or angio-
tensin receptor blockers) combined with either diuretic or
calcium-channel blocker or both in dual or triple formu-
lations, to achieve the recommended therapeutic targets.
Although the same guidelines do not provide clear
indications for choosing among different components
within the same drug class of antihypertensive agents [15,
16], some practical considerations for helping physicians
on the most appropriate therapeutic choice can be made on
the basis of the currently available evidence. First of all, it
would be useful to adopt antihypertensive strategies based
on single molecules that can be used both as monotherapy
and in fixed combination therapies, in order to limit the
‘‘pill burden’’ and ensure high level of adherence to pre-
scribed medications. Secondly, it should be limited the use
of molecules with proven evidence of cardiovascular pro-
tection, both in terms of regression of organ damage (e.g.
left ventricular hypertrophy, vascular alterations, renal
impairment) and of reduction of major cardiovascular
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events (e.g. myocardial infarction, stroke, heart failure, and
cardiovascular death). Thirdly, it should be preferred the
use of molecules which have demonstrated both in
monotherapy and in combination therapy to provide a
sustained antihypertensive efficacy and a favourable
metabolic profile. Finally, it should be favoured the use of
combination therapies with lower incidence of drug-related
side effects or adverse reaction compared to either com-
ponents or placebo.
In this volume of High Blood Pressure & Cardiovas-
cular Prevention, Karpov YA and colleagues reported the
main findings of the PRORYV-2 study [17]. This was an
open-label study which examined the effect of substituting
ineffective antihypertensive treatment with the fixed com-
bination therapy based on perindopril/amlodipine on clinic,
home and ambulatory blood pressure in a large group of
patients with uncontrolled hypertension at high/very high
cardiovascular risk. The authors used different dosage of
the two component (perindopril/amlodipine: 5/5, 10/5 or
10/10 mg) in a relatively large sample of adult hyperten-
sive patients in Russia. This led to a rapid (2 weeks) and
significant (p\ 0.001) reduction of clinic BP levels, which
was maintained after 3 months (-33.7/17.1 mmHg from
baseline). Of note, both 24-h ambulatory BP monitoring
and home BP monitoring confirmed the BP decrease. Thus,
the authors concluded that substituting ineffective antihy-
pertensive therapy with FDC perindopril/amlodipine
resulted in a rapid, pronounced and sustained antihyper-
tensive effectiveness.
With the well known limitations of the open-label design,
the studywas able to demonstrate that amore extended use of
rational, effective and well tolerated combination therapies
(mostly in fixed formulation) can rapidly and markedly
improve BP control rates and reduce BP variability in treated
uncontrolled hypertensive patients. Such an approach should
be encouraged and adopted in the clinical practice, to
improve the clinical management of hypertension and
achieve the recommended therapeutic targets.
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